WuXi Diagnostic rasied $150 million in its Seris B financing, led by Shiyu Investment, Thermo Fisher Scientific, ABC International, Sunland Fund, CCB Sci-Tech Innovation Fund, with continued support from existing shareholder Yunfeng Capital. The funds from this round will be used to expand the open innovation platform, accelerate the integration of diagnostic product research and development, and expand the company's global footprint.

CEC Capital Group served as the exclusive financial advisor for WuXi Diagnostics in this transaction.

WuXi Diagnostics is the first integrated diagnostic platform company in China focused on the research and development of diagnostics. Since its establishment in 2018, the company has been promoting the clinical practice of integrated diagnostics with its open platform driven by multiple platforms, multi-omics, and clinical data. In 2020, the company made remarkable progress, engaging in a global strategic partnership for COVID-19 testing with Thermo Fisher and Mayo Clinic through a license-out model to enter overseas markets and actively promote global anti-epidemic efforts. It also launched innovative diagnostic solutions based on integrated algorithm models, leading the way in non-invasive preoperative auxiliary diagnosis for China's biliary atresia collaboration network. Leveraging the integrated diagnostic concept and experience developed with Mayo Clinic, the company supported Beijing Anding Hospital affiliated to Capital Medical University in building a Chinese standard for individualized medication in psychiatric diseases. In addition, WuXi Diagnostics is working with innovative pharmaceutical companies, medical insurance, and the broader healthcare industry to build an innovative ecosystem for precision medicine.